{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:31:28Z","timestamp":1777926688496,"version":"3.51.4"},"reference-count":21,"publisher":"BMJ","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40425-017-0302-x","type":"journal-article","created":{"date-parts":[[2017,11,25]],"date-time":"2017-11-25T08:51:28Z","timestamp":1511599888000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas"],"prefix":"10.1136","volume":"5","author":[{"given":"Samantha N.","family":"Reiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakirthi","family":"Yerram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Modelevsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Grommes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,12,19]]},"reference":[{"key":"302_CR1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMra0708126","volume":"359","author":"PY Wen","year":"2008","unstructured":"Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492\u2013507.","journal-title":"N Engl J Med"},{"key":"302_CR2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396.","journal-title":"N Engl J Med"},{"key":"302_CR3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1215\/15228517-2007-062","volume":"10","author":"KR Lamborn","year":"2008","unstructured":"Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Oncology. 2008;10:162\u201370.","journal-title":"Neuro-Oncology"},{"key":"302_CR4","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","volume":"48","author":"R Stupp","year":"2012","unstructured":"Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbaly V, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48:2192\u2013202.","journal-title":"Eur J Cancer"},{"key":"302_CR5","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733\u201340.","journal-title":"J Clin Oncol"},{"key":"302_CR6","unstructured":"AVASTIN (bevacizumab) [package insert]. Genentech, Inc, San Francisco, CA; 2016. [ https:\/\/www.gene.com\/download\/pdf\/avastin_prescribing.pdf ]."},{"key":"302_CR7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11060-014-1714-9","volume":"122","author":"MC Chamberlain","year":"2015","unstructured":"Chamberlain MC. Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study. J Neuro-Oncol. 2015;122:329\u201338.","journal-title":"J Neuro-Oncol"},{"key":"302_CR8","unstructured":"KEYTRUDA (pembrolizumab) [package insert]. Merck & Co., Inc. Whitehouse Station, NJ; 2016. [ http:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf ]."},{"key":"302_CR9","unstructured":"OPDIVO (nivolumab) [package insert]. Bristol-Myers Squibb Company, Princeton, NJ; 2017. [ http:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf ]."},{"key":"302_CR10","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer. N Engl J Med. 2016;375:1823\u201333.","journal-title":"N Engl J Med"},{"key":"302_CR11","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354.","journal-title":"N Engl J Med"},{"key":"302_CR12","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/neuonc\/nou307","volume":"17","author":"AS Berghoff","year":"2015","unstructured":"Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wohrer A, Dieckmann K, Filipits M, Brandstetter A, Weller M, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncology. 2015;17:1064\u201375.","journal-title":"Neuro-Oncology"},{"key":"302_CR13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/neuonc\/nov172","volume":"18","author":"EK Nduom","year":"2016","unstructured":"Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncology. 2016;18:195\u2013205.","journal-title":"Neuro-Oncology"},{"key":"302_CR14","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17:976\u201383.","journal-title":"Lancet Oncol"},{"key":"302_CR15","doi-asserted-by":"crossref","unstructured":"Roth P, Valavanis A, Weller M. Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab. Neuro-Oncology. 2016;","DOI":"10.1093\/neuonc\/now265"},{"key":"302_CR16","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","volume":"34","author":"E Bouffet","year":"2016","unstructured":"Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, Durno C, Krueger J, Cabric V, Ramaswamy V, et al. Immune checkpoint inhibition for Hypermutant glioblastoma Multiforme resulting from germline Biallelic mismatch repair deficiency. J Clin Oncol. 2016;34:2206\u201311.","journal-title":"J Clin Oncol"},{"key":"302_CR17","doi-asserted-by":"crossref","unstructured":"Reardon DA, DeGroot JF, Colman H, Jordan JT, Daras M, Clarke JL, Nghiemphu PL, Gaffey SC, Peters KB. Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM). J Clin Oncol. 2016;34","DOI":"10.1200\/JCO.2016.34.15_suppl.2010"},{"key":"302_CR18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fonc.2015.00012","volume":"5","author":"L Ampie","year":"2015","unstructured":"Ampie L, Woolf EC, Dardis C. Immunotherapeutic advancements for glioblastoma. Front Oncol. 2015;5:12.","journal-title":"Front Oncol"},{"key":"302_CR19","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/neuonc\/now132","volume":"18","author":"ST Garber","year":"2016","unstructured":"Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, et al. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro-Oncology. 2016;18:1357\u201366.","journal-title":"Neuro-Oncology"},{"key":"302_CR20","first-page":"vi25","volume":"18","author":"RDAK TM","year":"2016","unstructured":"TM RDAK, Frenel JS, Santoro A, et al. ATIM-35. Results of the Phase IB KEYNOTE-028 Multi-Cohort Trial of Pembrolizumab Monotherapy in Patietns with Recurrent PD-L1 Positive Glioblastoma Multiforme (GBM). Neuro Oncol. 2016;18:vi25\u20136.","journal-title":"Neuro Oncol"},{"key":"302_CR21","doi-asserted-by":"crossref","unstructured":"Reardon DA, Omuro A, Brandes AA, et al. Randomized phase 3 study evaluating the efficacy and safety of Nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro-Oncology. 2017;19:iii21. https:\/\/academic.oup.com\/neuro-oncology\/article\/19\/suppl_3\/iii21\/3743874 #.","DOI":"10.1093\/neuonc\/nox036.071"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-017-0302-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:42:56Z","timestamp":1601055776000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-017-0302-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["302"],"URL":"https:\/\/doi.org\/10.1186\/s40425-017-0302-x","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"99"}}